dr. verstovsek discusses immunotherapy in myelofibrosis
Published 8 years ago • 640 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
1:19
dr. srdan verstovsek on jak2 inhibitors as a treatment for myelofibrosis
-
25:39
for myelofibrosis patients: latest on treatments from top doctor | dr. srdan verstovsek, md anderson
-
2:10
dr. verstovsek on accelerated phase myelofibrosis
-
2:16
dr. verstovsek on limitations of the current treatment landscape of myelofibrosis
-
1:45
evaluating cpi-0610 as treatment of patients with myelofibrosis
-
1:23:15
drs.verstovsek & mesa discuss latest myelofibrosis updates from #soho2021: https://bit.ly/3hfp1kc
-
3:51
new therapies for myelofibrosis
-
5:06
the prognosis of myelofibrosis
-
2:31
targeting cd47 in myelofibrosis
-
5:40
initiating treatment in myelofibrosis
-
4:45
myelofibrosis: long-term survival data and ruxolitinib use
-
1:58
significant developments in diagnosing pv
-
1:30
the importance of intervention in chronic phase myelofibrosis
-
1:53
sotatercept in patients with mpn-associated myelofibrosis and anemia
-
2:06
second-line myelofibrosis treatment – the potential of jak2 inhibitor ns-018
-
24:31
managing myelofibrosis in 2021 - dr. srdan verstovsek
-
20:42
beyond jak2 inhibitors: new targets and new agents
-
1:05
cpi-0610 demonstrates activity in patients with myelofibrosis following ruxolitinib failure
-
3:20
promising et, pv & myelofibrosis therapies in development